Why Regeneron Pharmaceuticals Dropped 11.3% in September
Despite sharing a series of positive news items with investors, shares of biotech-giant Regeneron Pharmaceuticals (NASDAQ: REGN) fell more than 11% in September, according to data from S&P Global Market Intelligence.
Regeneron and its partner Sanofi (NYSE: SNY) made a number of announcements during the month that captured the market's attention.
Here's an overview of the key developments from the month:
Source: Fool.com
Sanofi S.A. ADR Aktie
Deutliche Buy-Präferenz bei Sanofi S.A. ADR ohne Sell-Einschätzungen.
Ein leicht positives Kursziel von 55 € für Sanofi S.A. ADR gegenüber dem aktuellen Kurs von 52.0 € wird gesehen.